NanoViricides, a development-stage company, has reported that oral administration of FluCide anti-influenza drug candidates caused effective lung viral load decrease comparable to IV Administration.

Two different anti-influenza drug candidates, tested in an oral vs IV comparison, showed similar results that indicated strong oral effectiveness and demonstrated superior animal protection compared to oseltamivir (Tamiflu), a standard of care for influenza.

NanoViricides chairman and president Anil Diwan said; "We can easily increase the effectiveness of our drugs by increasing the oral dosage."

The lung viral load measured at 108 hours post-infection (hpi) showed that one of the orally administered FluCide drug candidates resulted in 1.30 log reduction (or 20X reduction) in lung viral load and matched the viral load reduction on the same drug candidate given as an IV injection.

Another drug candidate resulted in 1.23 log viral load reduction when given orally and 1.31 log viral load reduction when given as an injectable, according to the company.

Oseltamivir (Tamiflu, given orally at 40mg/kg/d) resulted in only 0.6 log viral load reduction (or only 4X reduction).

Furthermore, at 180 hpi, the lung viral load remained controlled at about the same level as at 108 hpi with the nanoviricide drug candidates.

According to the study data, number of lung plaques and plaque areas were consistent with the data from the lung viral load, and were minimal in the case of the nanoviricide drug candidates whether given as IV or orally.

Image: The transmission electron micrograph of negatively stained influenza virions, magnified approximately 100,000 times. Photo: Courtesy of Cynthia Goldsmith.